Jasper Therapeutics, Inc. Common Stock
$0.58
$0.01 (+1.89%)
$0.56Day Range$0.61
Key Statistics
Market Cap
$18.97M
Shares Outstanding
33.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 27, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$0.58
Day High
$0.61
Day Low
$0.56
Volume
505.3K
VWAP
$0.58
Prev Close
$0.57
Transactions
--
Acc. Volume
--
About Jasper Therapeutics, Inc. Common Stock
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283622 employees2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065(650) 549-1400IPO Sep 27, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001788028
- Composite FIGI
- BBG00QPZNP97
- Share Class FIGI
- BBG00QPZNPB4
- Ticker Root
- JSPR
- SIC Code
- 2836
About Jasper Therapeutics, Inc. Common Stock (JSPR) Stock
Jasper Therapeutics, Inc. Common Stock (JSPR) closed the 2026-09-16 session at $0.58, up 1.89% versus the previous close (+0.01). The stock opened at $0.58 and traded between $0.56 and $0.61 during that session. Session trading volume was 505K shares. The volume-weighted average price (VWAP) is $0.58.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Jasper Therapeutics, Inc. Common Stock has a market capitalization of $19.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. JSPR is listed on the XNAS exchange. The company employs approximately 22 people. Jasper Therapeutics, Inc. Common Stock is headquartered in REDWOOD CITY, CA. The recorded listing date is 2021-09-27.
On this page you can find market JSPR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.